Eliquis Reversal Protocol
For life-threatening or uncontrolled bleeding in patients taking apixaban (Eliquis), administer andexanet alfa as the first-line specific reversal agent, with dosing determined by the apixaban dose and timing of last intake. 1
Andexanet Alfa Dosing Algorithm
The 2020 ACC Expert Consensus Decision Pathway provides clear, dose-specific guidance 1:
Low-Dose Andexanet (400 mg IV bolus + 4 mg/min infusion × 120 minutes)
Administer when:
- Last apixaban dose ≤5 mg taken <8 hours prior, or timing unknown
- Last apixaban dose (any amount) taken ≥8 hours prior
High-Dose Andexanet (800 mg IV bolus + 8 mg/min infusion × 120 minutes)
Administer when:
- Last apixaban dose >5 mg taken <8 hours prior, or timing unknown
- Unknown apixaban dose taken <8 hours prior
Bolus administration rate: 30 mg/min for both dosing regimens 1
Evidence Supporting Andexanet Alfa
The 2024 ISTH guideline highlights that andexanet alfa demonstrated 93% median reduction in anti-FXa activity in the ANNEXA-4 study, with 80% of patients achieving excellent or good hemostatic efficacy at 12 hours 2. The study enrolled predominantly apixaban (51%) and rivaroxaban (37%) patients with major bleeding, most commonly intracranial (69%) or gastrointestinal (23%) hemorrhage 2.
Critical caveat: The ANNEXA-4 study excluded patients with apixaban levels <75 ng/mL, as these were considered clinically insufficient for reversal 1. If drug levels can be assessed without delaying urgent care, measurement should be performed before andexanet alfa administration.
Alternative Reversal Strategies
If Andexanet Alfa is Unavailable:
Use four-factor prothrombin complex concentrate (4F-PCC) or activated PCC (aPCC) 1. The 2020 ACC guideline acknowledges that while no randomized trials compare these agents to andexanet alfa, they represent reasonable alternatives when specific reversal is unavailable 1.
Activated Charcoal:
Consider for known recent ingestion within 2-4 hours 1. The FDA label confirms activated charcoal reduces apixaban absorption and plasma concentration 3.
What Does NOT Work
The FDA label explicitly states 3:
- Hemodialysis: Does not substantially impact apixaban exposure
- Protamine sulfate and vitamin K: Not expected to affect apixaban anticoagulant activity
- Monitoring limitations: PT, INR, aPTT, or anti-FXa activity testing is not useful for monitoring when PCCs are used
Safety Considerations
Thrombotic risk: In ANNEXA-4, thrombotic events occurred in 10% of participants, with 16 events occurring despite parenteral anticoagulant thromboprophylaxis 2. None of these patients had resumed oral anticoagulation at the time of the event.
Duration of effect: The pharmacodynamic effect of apixaban persists for at least 24 hours after the last dose (approximately two drug half-lives) 3. This is critical for timing of procedures and re-anticoagulation decisions.
Practical Implementation Points
- Do not delay treatment waiting for DOAC level results in urgent bleeding situations 4
- Consider patient-specific factors: Renal function significantly affects apixaban half-life (6-15 hours with normal function, up to 17 hours with severe renal impairment) 1
- Avoid in cardiac surgery: Andexanet alfa is not recommended before cardiac surgery requiring cardiopulmonary bypass, as it inhibits unfractionated heparin needed for extracorporeal circulation 4
- Supportive measures: Ensure adequate blood product support and hemodynamic management alongside reversal agents
Emerging Evidence
The 2024 ISTH guideline notes that the ANNEXA-I trial (comparing andexanet to usual care in intracranial hemorrhage) was stopped early after preplanned analysis 2, suggesting evolving evidence in this space. The most recent guidelines (2024 ISTH, 2020 ACC) consistently support andexanet alfa as the preferred agent when available, with non-specific hemostatic agents as backup options.